October 2019 - Page 5 of 21

TuesdayOct 29, 2019 10:55 am

Fortress Biotech Inc. (NASDAQ: FBIO) Starts Presentation at Dawson James Small Cap Growth Conference

Fortress Biotech (NASDAQ: FBIO) is an innovative biopharmaceutical company identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries, and at entities it founded and holds significant minority ownership positions. The product candidates span six large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders. The company advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. Fortress has established partnerships with some of the world's leading academic research institutions and…

TuesdayOct 29, 2019 10:55 am

CEL-SCI Corp. (NYSE: CVM) Starts Presentation at Dawson James Small Cap Growth Conference

CEL-SCI (NYSE: CVM) is at the forefront in the research and development of products for the treatment of cancer, autoimmune and infectious diseases. CEL-SCI believes that boosting a patient's immune system while still intact should provide the greatest possible impact on survival. The company's core capabilities include drug discovery, research, development and manufacturing of complex biological substances. CEL-SCI's phase 3 study is the largest phase 3 study in the world for the treatment of head and neck cancer, and after 8.5 years is very close to completion. Multikine, CEL-SCI's lead investigational therapy, is a potential therapeutic agent directed at enabling…

TuesdayOct 29, 2019 10:30 am

IMAC Holdings Inc. (NASDAQ: IMAC) Starts Presentation at Dawson James Small Cap Growth Conference

IMAC Holdings (NASDAQ: IMAC) combines life science advancements with traditional medical care for movement-restricting diseases and conditions. The company owns or manages outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. IMAC Regeneration Centers provide medical services for movement-restricting conditions. It has partnered with several active and former professional athletes, including brand ambassadors Ozzie Smith, David Price, Tony Delk and Mike Ditka. IMAC's outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries without surgery or opioids. For more information, visit the company's website at www.imacregeneration.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content…

TuesdayOct 29, 2019 10:30 am

Dyadic International Inc. (DYAI) Starts Presentation at Dawson James Small Cap Growth Conference

Dyadic International (NASDAQ: DYAI) is a global biotechnology company developing a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large-scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is leveraging its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and…

TuesdayOct 29, 2019 10:05 am

Medexus Pharmaceuticals Inc. (TSX.V: MDP) (OTCQB: PDDPF) Starts Presentation at Dawson James Small Cap Growth Conference

Medexus Pharmaceuticals (TSXV: MDP) (OTCQB: PDDPF) is a leading specialty pharmaceutical company with a strong North American commercial platform. The company's vision is to provide the best healthcare products to healthcare professionals and patients through the core values of quality, innovation, customer service and teamwork. Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The company's leading products are Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall™, an innovative allergy medication with a unique mode of action. For more information, visit the…

TuesdayOct 29, 2019 10:05 am

Caladrius Biosciences (NASDAQ: CLBS) Starts Presentation at Dawson James Small Cap Growth Conference

Caladrius Biosciences (NASDAQ: CLBS) is a clinical-stage biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Caladrius currently has four programs in the mid to late stages of clinical development. The company's product candidates include three cell therapies for cardiovascular diseases that are based on its autologous CD34+ cell therapy platform, two in phase 2 testing and one in late-stage development. In addition, Caladrius has an autoimmune product candidate, CLBS03, also in phase 2 testing. Caladrius' goal is to build a broad portfolio of novel and versatile…

TuesdayOct 29, 2019 9:40 am

Zynerba Pharmaceuticals Inc. (NYSE: ZYNE) Starts Presentation at Dawson James Small Cap Growth Conference

Zynerba Pharmaceuticals (NYSE: ZYNE) is the leader in pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, Autism Spectrum Disorder, 22q11.2 Deletion Syndrome (22q), and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). To meet these unmet medical needs, Zynerba is developing the next-generation transdermal cannabinoid therapeutics to improve the lives of patients. For more information, visit the company's website at www.zynerba.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news…

TuesdayOct 29, 2019 9:40 am

Ur-Energy (NYSE: URG) Starts Presentation at Dawson James Small Cap Growth Conference

Ur-Energy (NYSE: URG) engages in uranium mining and recovery operations, with activities including acquisition, exploration, development and operation of uranium mineral properties in the U.S. The company operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming. Ur-Energy has produced, packaged and shipped more than 2 million pounds from Lost Creek since the commencement of operations. The company's newest project, Shirley Basin, is one of the Pathfinder Mines assets acquired in 2013. Baseline studies necessary for permitting and licensing of the project are complete, the WDEQ application for permit to mine has been submitted, and work on other permits…

TuesdayOct 29, 2019 9:15 am

Interpace Diagnostics Group Inc. (NASDAQ: IDXG) Starts Presentation at Dawson James Small Cap Growth Conference

Interpace Diagnostics Group (NASDAQ: IDXG) is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. A leader in enabling personalized medicine, Interspace offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The company's molecular diagnostic tests deliver cutting-edge genetic and mutational analysis that help risk-stratify patient samples for thyroid, pancreatic, lung and other cancers to better inform treatment decisions. Supported by rigorous science, the company's molecular diagnostic tests allow healthcare providers the ability to avoid unnecessary surgeries and better assess the risk…

TuesdayOct 29, 2019 9:15 am

Can-Fite Biopharma Ltd. (NYSE: CANF) Starts Presentation at Dawson James Small Cap Growth Conference

Can-Fite BioPharma (NYSE: CANF) is an advanced clinical-stage drug development company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancers. Can-Fite's technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells. The company has several drugs in various stages of research and development. Its lead drug candidate, Piclidenoson, is currently in Phase III trials for…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: October 2019